Form 4: Theravance Biopharma Executive Aine Miller Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Aine Miller, SVP at Theravance Biopharma, disposed of 5,201 ordinary shares to cover tax obligations related to vesting restricted stock units.
Summary
- On August 20, 2024, Aine Miller, SVP at Theravance Biopharma, disposed of 5,201 ordinary shares.
- The shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- The transaction was with the issuer and did not involve an open market transaction.
- Following the transaction, Miller beneficially owns 160,632 ordinary shares.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard tax obligation fulfillment related to stock vesting.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of transaction: Disposal of ordinary shares. |
| 08/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.